Tu1021 Ledipasvir/Sofosbuvir With Ribavirin for the Treatment of Fibrosing Cholestatic Hepatitis C After Liver Transplantation

A S L D A b st ra ct s (164, 66%). Sixty subjects (24%) had cirrhosis. In LONESTAR-2, the majority of subjects were male (18, 75%), white (23, 96%), and had IL28B non-CC genotype (17, 71%). Twelve (50%) subjects had cirrhosis. In ELECTRON-2 the majority of subjects were male (63, 62%), white (85, 84%), and had IL28B non-CC genotype (59, 58%). Thirty subjects (30%) had cirrhosis. SVR12 data are reported in the table. Treatment was well-tolerated. Most common adverse events (>20% reported) were headache, fatigue, pruritus, asthenia, insomnia and flu-like symptoms (only among subjects who received PEG). Only 3 subjects discontinued treatment due to an adverse event. CONCLUSIONS: SOF-based regimens for 12 or 24 weeks are safe, well-tolerated, and an effective treatment option for patients with GT3 infection.